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ABSTRACT 1 
Aims: Delafloxacin is a fluoroquinolone antibiotic recently approved by the FDA for treatment of acute 2 
bacterial skin and skin structure infections (ABSSSI).  Delafloxacin was assessed for phototoxicity 3 
potential compared with a known phototoxic fluoroquinolone. 4 
Methods:  A Phase 1, investigator-blind, placebo/active-controlled, randomized, parallel-group study 5 
was conducted in 52 healthy male and female volunteers who received 200 or 400 mg of oral 6 
delafloxacin, 400 mg oral lomefloxacin or placebo once daily for 6 days.  This study evaluated the 7 
photosensitizing potential and possible wavelength dependency of delafloxacin by comparing the 8 
response of the skin to ultraviolet A (UVA), ultraviolet B (UVB) and visible radiation prior to and during 9 
administration of delafloxacin, lomefloxacin as a positive control, or placebo.  Adverse events were 10 
monitored throughout the study.  11 
Results:  Forty-seven subjects completed six days of dosing, and no evidence of phototoxicity was seen 12 
with delafloxacin.  Delafloxacin at 200 and 400 mg/day and placebo did not demonstrate differences in 13 
percent change from baseline in minimal erythema dose at all tested wavelengths (295 - 430 nm) by 14 
monochromator and solar simulator.  Lomefloxacin, the positive control, had statistically significant 15 
differences (p<0.05) at UVA wavelengths of 335 and 365±30 nm 24 hours after radiation exposure 16 
(maximum response).  The phototoxic index results were significantly higher for lomefloxacin at 335nm 17 
and 365nm compared to placebo and delafloxacin. 18 
Conclusions:  200 and 400 mg of delafloxacin administered for 6 days were well tolerated in healthy 19 
adult volunteers.  Delafloxacin and placebo failed to demonstrate a phototoxic effect but lomefloxacin, 20 
the positive control, demonstrated moderate phototoxicity. 21 
 22 
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Clinical trial registration numbers are not required for phase 1 studies.   23 
 24 
Key Words:  Phototoxicity, delafloxacin, fluoroquinolone, Structure-activity-relationship  25 
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INTRODUCTION 26 
 Antibiotics of the quinolone class have been associated with photosensitivity through the 27 
mechanism of phototoxicity.  This was noted with the earliest related compound, nalidixic acid.  28 
However with development of subsequent new generations of quinolone antibiotics, it is clear that the 29 
phototoxicity risk varies by compound and its associated structure activity relationships (SAR).
1
  While 30 
the mechanism involved in the phototoxic properties of fluoroquinolones (FQ) are not completely 31 
understood,  these reactions are more commonly associated with specific FQs, particularly lomefloxacin, 32 
clinafloxacin,  sitafloxacin, and sparfloxacin.
2-4
 As an example, lomefloxacin has been shown to be 33 
associated with a high incidence of significant photosensitivity (4-10%) and has been used as a positive 34 
control in phototoxicity studies. 
5,6
  35 
 In descending order, the rank of fluoroquinolone antibiotics (FQ) related to their phototoxic 36 
potential is as follows; lomefloxacin, fleroxacin, clinafloxacin, sparfloxacin, sitafloxacin, enoxacin 37 
pefloxacin, ciprofloxacin grepafloxacin, gemifloxacin, levofloxacin, norfloxacin, ofloxacin, 38 
trovafloxacin.
3,7-13
 Gatifloxacin and moxifloxacin have not been linked to phototoxic events.
14,15
 It had 39 
been easy to correlate the presence of a halogen at position 8 of the quinolone nucleus with phototoxic 40 
events.  To be certain, clinafloxacin, lomefloxacin, sitafloxacin and sparfloxacin feature either a fluorine 41 
or a chlorine at that position (Figure 1). However, Hayashi et al provided a more nuanced structure-42 
activity relationship to phototoxicity, employing the severity of erythema around rat eyes as the key 43 
biological data.  What they demonstrated was that – when substitution at N1 was small, such as an ethyl 44 
or cyclopropyl group, or when the N1 substitution was large and nonpolar, such as a 2,4-difluorophenyl 45 
– the presence of a halogen at C8 indeed resulted in severe erythema.  By contrast, they showed no 46 
erythema, in the presence or absence of a halogen at C8, when there was a large N1 substitution with 47 
more polarity, such as an 5-amino-2,4-diflourophenyl group.
1
 48 
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 Delafloxacin has three molecular features that collaborate to deliver a unique profile: at N1, it 49 
has a large, more polar 6-amino-3,5-difluoropyridine group; at C7, it is the only fluoroquinolone lacking 50 
completely a basic group and at C8 it features a halogen (chlorine) (Figure 1).  Structure-activity 51 
highlight the collaboration among all three in delivering its unique antimicrobial spectrum, including the 52 
unique activity against methicillin-resistant Staphylococcus aureus (MRSA).  
  
Delafloxacin is approved in 53 
the United States for the treatment of ABSSSI, where the causative agents include MRSA, and currently 54 
being studied for the treatment of community-acquired bacterial pneumonia. Our working hypothesis is 55 
that combinations of these unique molecular features will lead to differentiated profiles, including in the 56 
safety arena.  The Hayashi SAR suggests that the combination of the large, polar substitution at N1 with 57 
the halogen at C8 will lead to a positive profile in the arena of photosafety.  To that end and to further 58 
evaluate the phototoxicity potential of delafloxacin, phototesting was conducted in healthy human 59 
volunteers using a validated and standardized procedure with comparison to the positive control 60 
lomefloxacin as well as to placebo.  The study was designed to demonstrate the photosensitizing 61 
potential and possible wavelength dependency of delafloxacin, by comparing the response of the skin in 62 
the UVB range narrow wavebands at 290 nm, 300 nm, and 305 nm, UVA range wavebands at 335 63 
nm, and 365 nm, and in the visible range 430 nm, generated using a monochromator and solar 64 
simulator, prior to and during administration of delafloxacin, lomefloxacin, or placebo.   65 
Methods 66 
Dose Selection  67 
 The doses of delafloxacin were selected based on the pharmacokinetic and safety profiles 68 
demonstrated in early clinical studies.
16
 The 400 mg/day oral dose of delafloxacin (unformulated drug-in 69 
capsule) used in this study generated maximum plasma concentrations (Cmax) of delafloxacin, which 70 
overlap with those seen with the formulated 450mg oral tablet planned for market use.  The Cmax levels 71 
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were used for risk assessment as this plasma parameter is considered most predictive for 72 
phototoxicity.
17
  The dose of lomefloxacin was selected based on clinical data that indicate a phototoxic 73 
potential exists at >400 mg/day.
14
  74 
Study design 75 
 This Phase 1, investigator -blind, placebo- and positive-controlled, randomized, parallel-group 76 
study enrolled 52 healthy male and female volunteers. (Figure 2)  An independent ethics committee 77 
approved the study protocol, and the trial was conducted in accordance with the Declaration of Helsinki 78 
and International Conference on Harmonisation Good Clinical Practice.  All subjects provided written 79 
informed consent.  80 
 Subjects included in the study were men and non-pregnant women between 18 to 55 years of 81 
age, in general good health that had skin types I-III according to the Dermatology Scale of sun-reactive 82 
skin types.
18
 Subjects were restricted from using alcohol, caffeine, nicotine, and grapefruit juice until the 83 
final study evaluation was complete.  Volunteers were not enrolled in the study if they took any strong 84 
inhibitors (e.g. ketoconazole) or inducers (e.g. rifampicin) of CYP3A within one month prior to starting 85 
the trial, were on any chronic medications, had a history of clinical photosensitivity, or if they ever 86 
experienced hypersensitivity, allergic, or adverse reactions to FQs.  Potential subjects with clinically 87 
significant skin diseases (e.g., acne) or multiple tattoos also had to be excluded as these conditions could 88 
have affected/obscured skin reactions or restricted skin surface area available for phototesting. 89 
 Eligible subjects were admitted to a single center (DDS Medicines Research Limited, Dundee) 90 
and randomly assigned to receive blinded study drug in one of four treatment groups: delafloxacin (200 91 
mg or 400 mg, unformulated drug in capsule), placebo, or lomefloxacin 400 mg, each given orally daily 92 
for 6 days.  The details of phototesting technique are outlined below.  The endpoint used at each 93 
waveband tested was the baseline minimal erythema dose (MED) i.e. the minimum amount of 94 
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irradiation capable of producing a faint but definite erythema within the area of irradiation observed at 95 
24 and 48 hours.  In addition, a secondary analysis calculated the Phototoxic Index (Pl), obtained by 96 
dividing the baseline MED value for each individual, and the median MED value for each group, by the 97 
post-dose MED value.  Safety was assessed by 12-lead electrocardiograms (ECGs), physical examination, 98 
laboratory parameters, vital signs, and monitoring of adverse events.  99 
Phototesting Procedures  100 
 Clinical phototesting was performed using the monochromator and solar simulator (a simulator 101 
of midday equatorial sunlight, so proportionately producing a lot of the shorter, erythemogenic, UVB 102 
wavelengths) as previously reported in standard phototoxicity studies.
19
 The solar simulator can miss 103 
important UVA phototoxicity (as erythema from the shorter UVB wavelengths limits the dose of longer 104 
wavelengths that can be delivered) but testing with this helps to ensure we do not miss a complex 105 
phenomenon causing phototoxicity through a broad mixture of wavelengths).
20
 The skin of the mid-106 
upper back was identified as the test area in all subjects.  During the 3 weeks prior to study drug 107 
administration, as a screening procedure, the subject’s MEDs at each waveband were determined over 3 108 
consecutive days.  On the first day, a geometric range of radiation dose was used.  This resulted in an 109 
approximate MED for each waveband.  On the subsequent days, the precise MED was determined by 110 
narrowing the gap between the MED and the no-response value, using smaller increments of 20%.   111 
Subjects were suitable for enrollment only if the MED was found to be within normal limits.    112 
 The MED was determined for ultraviolet and visible light wavebands 290±5 [half-maximum 113 
bandwidth] nm, 300±5 nm, 305±5nm, 335±30nm and 365 through to 430±30 nm, which cover the 114 
biologically important regions:  290-315 nm (UVB), which is mainly responsible for sunburn reactions; 115 
315-400 nm (UVA), which is commonly involved in drug-induced cutaneous phototoxicity; and 400-700 116 
nm (visible spectra).  Each subject was examined for evidence of erythema at 0 (prior to dosing) and at 117 
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5, 10, 15 and 30 minutes post-irradiation for immediate reactions.  Subjects were re-examined at 24 and 118 
48 hours post-irradiation for delayed reactions.  Previous work on the fluoroquinolones has recorded 119 
maximal photosensitivity at 24 hours post-dose.
14
 120 
 During Study Days 1 through 6, subjects received the assigned dose of study drug.  On Study Day 121 
5, 2 hours post-dosing (near Cmax plasma levels), a range of radiation doses were administered at each 122 
waveband and an approximate MED was calculated for each waveband.  If it became apparent that the 123 
subject had become very photosensitive, the phototesting dosage schedule was adjusted.  On Study Day 124 
6, the exact MED was determined by narrowing the gap between the MED and the no-response values 125 
using small increments of 20% of the irradiation dose.  Assessments were performed of the Study Day 6 126 
phototesting sites on Days 7 and 8 (approximately 24 and 48 hours post-irradiation). The results of tests 127 
performed on Study Day 6 and assessments made on Days 7 and 8 were to be clinically acceptable prior 128 
to discharge on Study Day 8.  Subjects with a PI >5 at Study Day 7 were to undergo careful 129 
photoprotection and repeat testing on Study Day 21.  130 
 Any subjects whose MED at any waveband was significantly reduced (>40%) during the study 131 
drug administration were re-tested at the sensitive wavebands on a daily basis until their MED returned 132 
to within 40% of baseline. Phototesting was conducted, as routine with all wavebands through to 133 
430±30nm. There were plans to test to longer wavebands if photosensitivity was detected to the 134 
430±30nm waveband and if there had been significant 400±30nm waveband photosensitivity, short and 135 
long-pass filters were to be used to determine whether or not there was visible wavelength 136 
phototoxicity with its possible implications for the retina. 137 
 If a subject had a PI >5 on Study Day 7, this subject was required to be re-examined for delayed 138 
erythema/pigmentation on Study Day 21.   139 
Statistical analyses 140 
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 For the sample size requirement calculations, it was assumed, based on earlier studies, that the 141 
standard deviation about mean PI was 1.68 and 1.43 for lomefloxacin and placebo, respectively.  The 142 
sample size was determined to give 90% power to detect as significant at P≤0.05 with two-tailed testing 143 
a difference between mean phototoxic indices of ≥2.  144 
The primary outcome measure of the study was the change in MED at each waveband within 145 
subject/group comparing their baseline with on drug/placebo value.  Data for each waveband tested 146 
were analyzed separately where the maximum PI indicated the phototoxic potential of the study drug. 147 
The significance of within-subject changes in MED at each wavelength within each dosing group was 148 
assessed by means of the Wilcoxon’s signed rank test.  149 
 Based on a previously-defined, PI values scoring system, phototoxicity was graded as absent 150 
(PI<1.4), mild (PI 1.4-3), moderate (PI ranging from >3-6), or severe (PI > 6) at each testing timepoint.
21
 151 
The phototoxic index PI was compared between treatment groups using the Kruskal-Wallis equality of 152 
populations test to first test for any differences between groups and then, for pairwise comparisons 153 
between groups, the Mann-Whitney U test (Wilcoxon rank sum test) and related methods for 154 
confidence intervals for differences in medians as implemented in Stata 14 (Stata 14, StataCorp, Texas, 155 
2016).   156 
RESULTS 157 
Subject demographics 158 
 Fifty-two (52) subjects were randomized in the study and took study drug, with 13 subjects each 159 
receiving delafloxacin 200 mg, delafloxacin 400 mg, lomefloxacin 400 mg, or placebo, respectively.  160 
Forty-five subjects completed the study; 2 additional subjects in the lomefloxacin dosing group 161 
completed the 6-day dosing period but one subject withdrew consent before completing all study 162 
procedures and another subject did not return for Study Day 21 phototesting.  Both of these subjects 163 
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were included in the phototoxicity analyses. (Figure 2)  One, 2 and 1 subjects on delafloxacin 200mg, 164 
delafloxacin 400mg and placebo, respectively, dropped from the study due to adverse events, discussed 165 
further in safety section.  No blind breaks were reported.  Among all randomized subjects, no 166 
statistically significant differences were observed among the dosing groups in gender, age, height, or 167 
weight. The majority of the subjects were male (65%) and white (100%).  The mean age of all 168 
randomized subjects was 33.7 years (range from 18 to 54 years). The mean weight was 74.8 kg (range 169 
from 51 to 97 kg).  The mean height was 173 cm (range from 152 to 194 cm).  170 
Outcomes 171 
 Subjects who completed at least 6 days of dosing (N=47) were included in the analyses of 172 
phototoxicity.  At doses of 200 and 400 mg/day, delafloxacin did not demonstrate clinically significant, 173 
phototoxic potential at any wavelengths tested (295 to 430 nm and solar simulator), while the active 174 
comparator, lomefloxacin, demonstrated a moderate degree of phototoxicity at UVA wavelengths 335 175 
nm and 365 nm (Tables 1 and 2). 176 
 There was no evidence of phototoxicity revealed in the placebo group.  There were no 177 
statistically significant differences from zero in percent change from baseline in MED observed within 178 
the delafloxacin 200 mg/day and 400 mg/day dosing groups or the placebo group at each wavelength 179 
tested (295±5 nm to 430±30 nm and solar simulator).  There were no significant differences between 180 
placebo and either delafloxacin regimen in percent change in MED from baseline.   181 
 Statistically significant differences from zero in percent change from baseline in MED were 182 
observed at UVA wavelengths 335 nm and 365 nm in the lomefloxacin group (p<0.05).  At these same 183 
wavelengths, statistically significant differences in percent change from baseline in MED were also seen 184 
when lomefloxacin was compared to both delafloxacin dosing groups and the placebo group.  A 185 
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summary of mean percent change from baseline to Day 7 in MED by monochromator waveband and 186 
solar simulator is presented in Table 1. 187 
 Substantially higher PI values were also demonstrated by the lomefloxacin group compared to 188 
the other 3 dosing groups at wavelengths of 335 nm and 365 nm.  The maximum PI in the lomefloxacin 189 
group at these wavelengths (6.8 and 10.0, respectively) greatly exceeded those in the other 3 dosing 190 
groups (1.4 and 1.4, respectively, in the delafloxacin 200 mg dosing group, 2.1 and 1.5, respectively, in 191 
the delafloxacin 400 mg dosing group, and 1.8 and 1.5, respectively, in the placebo group) (Table 2).  192 
Dot plots of the outcomes at 335±30 nm and 365±30nm are displayed in figures 3 and 4.  The difference 193 
in PIs across the 4 groups for 365±30nm waveband is unlikely to be a chance finding (P=0.0001).  The 194 
difference in medians (or strictly, the median of the differences) for lomefloxacin vs. placebo is 3.9 (95% 195 
CI 2.0 to 6.9, P<0.0001). The difference in medians for delafloxacin 200mg/day vs. placebo was 0 (95% CI 196 
–0.3 to 0.2, P=0.78).  The difference in medians for delafloxacin 400mg/day vs. placebo was 0 (95% CI –197 
0.3 to 0.2, P=0.95). No visible wavelength phototoxicity was detected.    198 
 None of the subjects in the delafloxacin 200 mg/day group had abnormal MED responses 199 
(reduction of >40% from baseline) on Study Day 7.  Two subjects in the delafloxacin 400 mg group and 1 200 
placebo subject had abnormal MED responses on Study Day 7 and returned for day 8 assessments, 201 
which were normal. 202 
 All 12 subjects in the lomefloxacin group had abnormal MED responses at day 7; 6 of these 203 
subjects returned to less than 40% baseline by day 9 and so did not require further testing.   Six of the 204 
lomefloxacin subjects required further phototesting on Study Day 21 because of persistent 205 
photosensivity at day 9; one subject did not return for this follow-up.  Repeat phototesting in these 206 
subjects showed that the photosensitivity had resolved by day 21. There was no evidence of abnormal 207 
pigmentation at Study Day 21 in any of the subjects. 208 
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Safety  209 
 The most common study drug-related adverse event in the delafloxacin 200 mg and 400 mg 210 
groups were associated with the digestive system (31% and 38% respectively).  Five subjects in the 211 
delafloxacin 400 mg/day and 1 subject in the placebo group reported diarrhea during the study, all of 212 
which were considered to be probably or possibly related to study drug.  Additionally, all cases of 213 
diarrhea were sporadic, mild, or moderate in intensity, and resolved spontaneously.  Four subjects (1 214 
delafloxacin 200 mg, 2 delafloxacin 400 mg, and 1 placebo) were prematurely discontinued from study 215 
drug due to the occurrence of at least one adverse event.  Three of these subjects withdrew due to 216 
adverse events considered possibly or probably related to study drug (headache in one delafloxacin 400 217 
mg subject; diarrhea and abdominal pain in one delafloxacin 400 mg subject; migraine, myasthenia and 218 
dizziness in a placebo subject).  No clinically meaningful patterns of changes in vital signs values, ECG, 219 
and laboratory values were observed during the study.  220 
DISCUSSION 221 
 While a halogen atom at position 8 of a FQ can expand the spectrum of antibacterial activity and 222 
improve oral bioavailability, they have been rarely used in FQs due to the severe phototoxicity caused by 223 
this substitution.
4
  Attempts to reduce or avoid phototoxicity have led to the development of FQs with a 224 
methoxy group at position 8.  While these FQs did not cause phototoxicity in clinical studies, this 225 
substitution produced agents with decreased antibacterial activity.
1
  However SAR work has shown that 226 
the phototoxic potential of FQs may be influenced by other substitutions on the quinolone core 227 
molecule.  The presence of a large bulky substitution at position 1 mitigated phototoxicity associated 228 
with the halogen at position 8 in an animal model.  This work demonstrated that with specific 229 
substituents, new types of 8-halogeno quinolones with high levels of antibacterial activity but without 230 
severe phototoxicity could be developed.
1
   231 
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 The results in this clinical study are consistent with the findings in the previously reported 232 
animal study, where a compound with an aminodifluoropyridine at position 1, as seen with delafloxacin, 233 
appears to have less risk for phototoxicity even when there is a halogen at position 8 in the quinolone 234 
molecule.  At dosages of 200 and 400 mg/day, delafloxacin failed to demonstrate a significant 235 
phototoxic effect.    It is important to note that Cmax levels were used for risk assessment as this plasma 236 
parameter is considered most predictive for phototoxicity.
17
  The 400 mg/day oral dose of delafloxacin 237 
in this study was unformulated drug-in capsule and generated a Cmax of delafloxacin, which overlaps with 238 
that seen with the formulated 450mg oral tablet currently approved for use in the U.S.  No differences in 239 
phototoxic effect were seen between the 200 and 400 mg/day doses.  The classical pattern of 240 
fluoroquinolone phototoxicity as detected in previous phototoxicity studies with other fluoroquinolones 241 
(i.e., a UVA phenomenon maximal at 24 hours) was not seen with delafloxacin.  However, lomefloxacin 242 
revealed phototoxicity within the moderate phototoxic index group at the 335 and 365±30 nm 243 
wavebands, maximal at 24 hours, with susceptibility clearing within 48 hours after drug cessation.  244 
Phototoxicity was not demonstrated in the placebo group. Using the solar simulator, the mean and 245 
median phototoxic index of the lomefloxacin group was higher than in the other 3 dosing groups, with 246 
statistically significant differences between lomefloxacin and both the placebo and 200 mg delafloxacin 247 
group.  Whether measured via change in MED or by PI, delafloxacin 200 and 400 mg doses had no 248 
phototoxic effect and were comparable to placebo. (Tables 1 and 2) 249 
There were plans to test to longer wavebands if photosensitivity was detected to the 430±30nm 250 
waveband and if there had been significant 400±30nm waveband photosensitivity, short and long-pass 251 
filters were to be used to determine whether or not there was visible wavelength phototoxicity with its 252 
possible implications for the retina.   If a drug was found to be significantly photosensitizing and for the 253 
photosensitivity to extend into the visible part of the spectrum then this would have potential 254 
implications for adverse effects on the retina. However, in this study, as there was no significant 255 
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photosensitivity detected at the UVB and UVA wavebands tested, there was therefore no indication or 256 
requirement to extend phototesting into the visible part of the spectrum.  257 
 258 
While informative, phase 1 studies, with a focus on a small number of healthy volunteers, may 259 
miss toxicities encountered in clinical practice.  In a pooled analysis of 741 subjects from two Phase 3 260 
trials of delafloxacin in the treatment of ABSSSI, there were no cases of photoxicity reported.
22
  261 
Additionally, monitoring in clinical use will be prudent.  262 
 263 
Conclusion 264 
 Oral delafloxacin was well tolerated in this study, with the most common event being mild to 265 
moderate gastrointestinal events.  Of note, this study used unformulated drug in capsule which 266 
generated a Cmax of delafloxacin which overlaps with that seen with the formulated 450mg tablet 267 
currently approved for use in the US.  Previous studies have shown differences in phototoxic potential 268 
between the fluoroquinolones.  The results of this trial showed that both doses of delafloxacin were 269 
safe, well tolerated, and did not demonstrate clinically significant phototoxic potential at any 270 
wavelength tested in healthy adult volunteers. 271 
 272 
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Tables and Figures 336 
Table 1.  Mean Percent Change from Baseline to Day 7 in MED by Monochromator Wavelength and 337 
Solar Simulator 338 
 339 
















DLX 200 mg (n= 12) 
DLX 400 mg (n= 11) 
LMX 400 mg (n= 12) 
PBO (n=12) 
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-0.4 (17.43)  
11.9 (18.37)  
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DLX 400mg  
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400 ± 5 nm 
-2.8 (6.57) 
-9.1 (17 .43) 
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DLX 400mg  
LMX 400mg  
PBO 
430 ± 5 nm 
0.00 (0.0)  
0.00 (0.0)  
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NA= not applicable 340 
* = statistically significant (p<0.05) 341 
§
 P-value comparing MED to baseline within treatment groups using Wilcoxon signed rank test. 342 
§§ 
P-value comparing MED between treatment groups using Wilcoxon rank sum test. 343 
 344 
 345 
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Table 2.  Phototoxic Index (PI) Results on Study Day 7 Based on Wavelength and Solar Simulator 346 
 347 









DLX 200 mg (n= 12) 
DLX 400 mg (n= 11) 
LMX 400 mg (n= 12) 
PBO (n=12) 

















DLX 200mg  
DLX 400mg  
LMX 400mg  
PBO 
300 ± 5 nm 
















DLX 200mg  
DLX 400mg  
LMX 400mg  
PBO 

















DLX 200mg  
DLX 400mg  
LMX 400mg  
PBO 

















DLX 200mg  
DLX 400mg  
LMX 400mg  
PBO 
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NA= not applicable 348 
* = statistically significant (p<0.05) 349 
Min = minimum 350 
Max = maximum 351 
§ 
P-value comparing MED between treatment groups using Wilcoxon rank sum test. 352 
 353 
 354 




Figure 1  
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AE (n = 1)
Reasons
AE (n = 2)
Reasons
2 patients completed the 
dosing period on day six and 
withdrew consent.  Their 
phototesting was included in 
results.  (n = 2)*
Lost to follow up (n = 1)
Figure 2. CONSORT diagram of patient disposition
Reasons
AE (n = 1)
* Subjects who completed at least 6 days of dosing (N=47) were included in the analysis of phototoxicity.




Figure 3  
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Figure 4  
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